AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Enrollment closed for phase II study of Femprox.(Brief Article)
2002 MAR 7 - (NewsRx.com & NewsRx.net) -- NexMed, Inc., (NEXM) a developer of innovative topical treatments based on its proprietary drug delivery technology, has closed enrollment for its Phase II study with the Femprox cream treatment for female sexual arousal disorder (FSAD).
Approximately 100 patients are enrolled at 15 clinics throughout the U.S. The Phase II "at home use" study is randomized, double-blind, placebo-controlled, and designed to investigate the efficacy and safety of the Femprox cream in premenopausal women diagnosed with FSAD. Femprox is applied topically and incorporates alprostadil with the NexACT platform drug delivery technology.
Dr. James Yeager, NexMed, commented, "We are completing a well-designed and well-controlled 'at home use' clinical study for FSAD. Our Phase II clinical trial is intended to examine the safety and efficacy of Femprox in the at-home setting. The primary endpoint is success in ...
- Positive phase 2 results reported for Alista in premenopausal women with FSAD.
- Newspaper article from: Biotech Week August 11, 2004 700+ words
...data from a recently completed phase 2 clinical trial demonstrated...female sexual arousal disorder (FSAD) when compared with placebo...questionnaire. VIVUS is entering phase 3 clinical development with...tissues in females. ALISTA phase 2 clinical data in postmenopausal...
- NexMed to Initiate 400 Femprox(R) Clinical Study in China For Female Sexual...
- Press release article from: PR Newswire March 2, 2004 700+ words
...to initiate a 400-patient Phase 3 study for Femprox(R) in...female sexual arousal disorder (FSAD). Femprox(R), recently...enhancer. In NexMed's U.S. Phase 2 study for Femprox, ninety...menopausal women diagnosed with FSAD completed the four-week clinical...
- Study confirms at least two subtypes of FSAD.(Gynecology)
- Magazine article from: OB GYN News Finn, Robert March 1, 2005 700+ words
...diagnosis of female sexual arousal disorder (FSAD), DSM-IV-TR requires "persistent...women reporting the genital subtype of FSAD, 26 reporting the subjective subtype...both the control women and the women with FSAD, the erotic film resulted in significant...
- Harvard Scientific Completes Animal Toxicity Studies For FSAD -- "Female Sexual...
- Press release article from: Business Wire September 23, 1998 700+ words
...for female sexual arousal disorder ("FSAD"). In the studies, lyophilized liposomal...renowned authorities have demonstrated that FSAD is caused in large part by poor blood flow...Goldstein on October 23-25, at the FSAD conference. The Company believes that...
- Neutron Signs Letter of Intent to Acquire up to 67% Interest in Development...
- Press release article from: PR Newswire March 10, 2004 700+ words
...treatment of Female Sexual Arousal Disorder (FSAD). - Endeavors to become one of the first...deliver a product for the treatment of FSAD. Neutron Enterprises, Inc.(NASDAQBB...treatment of Female Sexual Arousal Disorder (FSAD). The Company is developing additional...
- Zestra for Women(TM) Increases Sexual Pleasure in Women With FSAD (Female...
- Press release article from: PR Newswire November 20, 2001 700+ words
...WOMEN WITH FEMALE SEXUAL AROUSAL DISORDER. Zestra for Women(TM) was studied in 10 women with Female Sexual Arousal Disorder (FSAD), in at-home use. Zestra for Women(TM) showed statistically significant (P less than .05) benefits over placebo in...
- NexMed's Female Sexual Arousal Disorder Product Enters Phase 2 Clinical Trial.
- Press release article from: PR Newswire May 21, 2001 700+ words
...that it has initiated a Phase 2 clinical study with...sexual arousal disorder ("FSAD"). The Phase 2 study is randomized...The initiation of this Phase 2 study on Femprox(TM...commercial treatment for FSAD." Dr. Mo further commented...
- NitroMed and the University of Texas at Austin Report Phase II Clinical Results...
- Press release article from: PR Newswire June 26, 2000 700+ words
...reported the positive Phase II clinical results of NitroMed's FSAD therapeutic NMI...component to treating FSAD," said Manuel Worcel...870's successful Phase I and Phase II trials...The results of this Phase II study are encouraging...therapeutic for both FSAD and ED." The ...